In this report, Fortune Business Insights has predicted that this market, which was valued at US$ 536.3 Mn in 2017, reach US$ 1,076.5 Mn and in doing so, it will exhibit a CAGR of exhibiting a CAGR of 9.1%.
The Global Prothrombin Complex Concentrates Market is likely to gain traction due to the significant drop in demand for its counterpart fresh frozen plasma (FFP). Fortune Business Insights has published a report, titled ‘Prothrombin Complex Concentrate Market Size, Share and Global Trend by Product Type (3-factor PCC, 4-factor PCC), Application (Congenital and Acquired Coagulation Factor deficiency), End User (Hospitals, Ambulatory Surgical Centers) and Geography Forecast till 2025.
Some of the major companies that are present in the Global Prothrombin Complex Concentrates Market are;
- CSL Behring
- Octapharma Sweden
- Kedrion Biopharma
- China Biologic Products Holdings, Inc.
- Other players
Clinical studies have proven that fresh frozen plasma needed much longer infusion time, as compared to prothrombin complex concentrate (PCC). Besides infusion time, PCC possess some other advantages over FFP.
Some notable properties that have led to PCC’s increasing adoption are its ability to reconstitute in a short span. Furthermore, PCC is available easily due to its lack of blood group specificity. In addition to the aforementioned factors, a better safety profile of PCC has influenced users to prefer them over fresh frozen plasma.
Leading Companies Are Focusing On Setting Up Plasma Collection Centres
As companies are realizing the clinical advantages of PCC over fresh frozen plasma, they are now focusing on research and development of PCC. It is seen that there is an emphasis on stocking up plasma from blood that is required in PCC. To ensure that these needs are sufficed, leading companies such as Grifols SA and Octapharma are putting in increased efforts towards setting up plasma collection centres across several countries around the world.
Kcentra Has Changed the Face of PCC, Globally
Ever since Kcentra was approved by the FDA, it has been adopted by many healthcare professionals worldwide. Kcentra has proven efficient in restoring blood coagulation, as it is packed with certain factors that help replenish various clotting factors. Kcentra played a major role in treatments for patients who are undergoing warfarin therapy.
Browse Complete Report Details at https://www.fortunebusinessinsights.com/industry-reports/prothrombin-complex-concentrate-pcc-market-100102
Warfarin may lead to sever and acute blood loss and to minimize such losses and restoring coagulation factors, Kcentra has been proved beneficial. Therefore, the use of PCC in warfarin induced bleeding is leading to increased adoption which in turn has boosted the global market.
Segmentation for Prothrombin Complex Concentrates Market are;
By Product Type
- 3-factor PCC
- 4-factor PCC
- Congenital Coagulation Factor Deficiency
- Acquired Coagulation Factor deficiency
By End User
- Ambulatory Surgical Centers
Increasing Government Initiatives and Funding to Boost the Global Market
Recent updates in policies regarding usage approval have boded well for prothrombin complex concentrates. There has been a relaxation in usage of Prothrombin Complex Concentrates (PCC) in treating bleeding disorders, globally. This has encouraged research analysts and related personnel to conduct more clinical trials and propose newer usage concepts to the regulatory authorities. Moreover, increasing government funding promoting the use of PCC in surgical procedures is boosting the global. Proven clinical efficiency of PCC has encouraged governments across the world to promote the use of PCC for treating unwanted bleeding in surgical procedures. Furthermore, few alternatives are available to treat bleeding and the existing alternatives do not come close to the standards set by PCC. This in turn has led to an increase in demand for PCC and subsequently boosted the global PCC
More Trending Topics from Fortune Business Insights: